A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China - Trial NCT06352190
Access comprehensive clinical trial information for NCT06352190 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shouyao Holdings (Beijing) Co. LTD and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shouyao Holdings (Beijing) Co. LTD
Timeline & Enrollment
Phase 1
May 01, 2024
Jun 01, 2024
Primary Outcome
Total radioactivity in plasma PK: Cmax,Total radioactivity in plasma PK: Tmax,Total radioactivity in plasma PK: AUC0-t,Total radioactivity in plasma PK: t½,Total radioactivity in plasma PK: CL/F,Whole blood to plasma total radioactivity ratio,Cumulative total radioactivity in urine and faeces,Metabolic profiling in plasma, urinary and fecal excretion
Summary
This is a single-center, open-label, non-randomized, single dose study in healthy male
 subjects designed to assess mass balance recovery, metabolite profile and metabolite
 identification of radio-labeled SY-5007 administered orally.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06352190
Non-Device Trial